Bipolar Disorder Treatment Insurance Claim Denied? How to Appeal

Insurance denials for bipolar disorder treatment — whether for mood stabilizers, atypical antipsychotics, intensive outpatient programs, or inpatient psychiatric hospitalization — are among the most disruptive and legally challengeable decisions an insurer can make. The Mental Health Parity and Addiction Equity Act (MHPAEA) was specifically designed to prevent insurers from applying more restrictive criteria to bipolar disorder treatment than they apply to comparable medical conditions. If your claim was denied, federal law is on your side.

Why Insurers Deny Bipolar Disorder Treatment Claims

Bipolar disorder treatment denials follow predictable patterns across major insurers.

Not medically necessary per internal criteria. The insurer's utilization reviewer determined that the requested level of care or medication does not meet their internal clinical criteria. These criteria are often more restrictive than the American Psychiatric Association (APA) Clinical Practice Guidelines for Bipolar Disorder, which constitute the accepted standard of care.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization required. Many bipolar disorder treatments — particularly atypical antipsychotics (quetiapine, lurasidone, cariprazine), mood stabilizers at higher doses, and all levels of intensive outpatient or inpatient care — require prior authorization. Missing this step triggers an administrative denial regardless of clinical appropriateness.

Step therapy not completed. For bipolar medications, insurers often require trials of older, less expensive agents (lithium, valproate, older antipsychotics) before approving newer branded medications. When your psychiatrist prescribed a newer agent due to documented tolerability issues or specific clinical features of your bipolar presentation, step therapy requirements can be challenged with documentation of contraindications or prior failures.

Level of care criteria more restrictive than medical equivalents. Under MHPAEA (29 U.S.C. § 1185a), your insurer cannot impose criteria for psychiatric inpatient admission — for example, requiring active suicidality — that are more restrictive than the criteria it applies for medical inpatient admission for comparable conditions. This is one of the most commonly violated parity requirements.

Benefit limit reached. Many plans impose annual limits on psychiatric inpatient days or outpatient mental health visits that they do not apply to comparable medical/surgical benefits. These quantitative treatment limitations violate MHPAEA if the equivalent medical benefit has no comparable limit.

How to Appeal

Step 1: Request the specific clinical criteria used to deny

Under ACA regulations (42 U.S.C. § 300gg-19), the insurer must disclose the specific clinical criteria applied. Request this document in writing the same day you receive the denial. Also request the MHPAEA comparative analysis under 29 C.F.R. § 2590.712(c)(4) — the insurer must provide this within 30 days.

Step 2: Identify the parity violation

Compare the insurer's criteria for your denied bipolar treatment to the criteria applied to a comparable medical condition. If the insurer requires active suicidality for psychiatric inpatient but not cardiovascular instability for medical inpatient, that is an NQTL violation under MHPAEA. If the plan limits psychiatric visits to 30 per year but imposes no limit on comparable medical specialist visits, that is a quantitative treatment limitation violation.

Step 3: File a Level 1 internal appeal within 180 days

Under the ACA (42 U.S.C. § 300gg-19), you have 180 days from the denial date. Your appeal letter should cite MHPAEA (29 U.S.C. § 1185a) explicitly, include your psychiatrist's letter addressing each denial criterion, attach the APA Clinical Practice Guidelines for Bipolar Disorder supporting the requested treatment, and document the specific parity violation with a side-by-side comparison of MH vs. medical benefit criteria.

Step 4: Invoke MHPAEA through the comparative analysis request

State in your appeal: "This denial violates the Mental Health Parity and Addiction Equity Act because this plan applies criteria to this bipolar disorder treatment that are more restrictive than those applied to comparable medical/surgical benefits." Request that the insurer produce the CAA 2021 comparative analysis demonstrating that its behavioral health criteria are equivalent to medical criteria — failure to produce it strengthens your complaint.

Step 5: Request a peer-to-peer review

Your treating psychiatrist should call the insurer's medical director. Peer-to-peer reviews are particularly effective for bipolar disorder level-of-care disputes because the treating psychiatrist can explain the specific clinical presentation, risk factors, and why a less intensive level of care is clinically insufficient.

Step 6: File regulatory complaints in parallel

For ERISA employer plans: file with the Department of Labor EBSA at dol.gov/agencies/ebsa. For marketplace plans: file with your state insurance commissioner. States with aggressive MHPAEA enforcement — California, New York, Illinois, Colorado — have issued findings against major insurers for exactly the type of violations common in bipolar disorder denials.

What to Include in Your Appeal

• Denial letter and EOB)" class="auto-link">Explanation of Benefits (EOB)
• Written request for the CAA 2021 comparative analysis under 29 C.F.R. § 2590.712(c)(4)
• Your Summary Plan Description showing mental health and comparable medical benefit structures
• Psychiatrist letter of medical necessity addressing each denial criterion
• APA Clinical Practice Guidelines for Bipolar Disorder supporting the requested treatment
• LOCUS assessment if applicable (for level-of-care disputes)
• Side-by-side comparison of bipolar disorder benefit criteria vs comparable medical benefit criteria
• Documentation of prior medication trials with dates, doses, and clinical outcomes (for step therapy disputes)

Fight Back With ClaimBack

Bipolar disorder treatment denials frequently violate MHPAEA's core prohibition on more restrictive behavioral health criteria. Federal courts have consistently enforced this law, and the 2024 MHPAEA final rules give DOL and HHS increased enforcement authority to penalize these violations. Insurers know they are exposed when they apply more restrictive criteria to psychiatric conditions than to comparable medical conditions. ClaimBack generates a professional appeal letter in 3 minutes that cites MHPAEA, the APA Clinical Practice Guidelines, and the specific comparative analysis rights that apply to your bipolar disorder denial.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal